Tvardi Therapeutics, Inc.
TVRD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.17 | 0.02 | 0.00 |
| FCF Yield | -831.44% | -45.90% | -39.08% | -870.96% |
| EV / EBITDA | -0.22 | -1.35 | -1.31 | 0.03 |
| Quality | ||||
| ROIC | -139.18% | -78.38% | -49.49% | -38.53% |
| Gross Margin | 88.62% | 69.32% | 82.05% | 93.25% |
| Cash Conversion Ratio | 0.86 | 1.21 | 0.87 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -44.55% | -3.08% | -32.33% | 2,844,920.54% |
| Free Cash Flow Growth | -194.50% | -17.44% | 70.20% | -930.26% |
| Safety | ||||
| Net Debt / EBITDA | -0.10 | 1.31 | 0.93 | 0.11 |
| Interest Coverage | -6.58 | 0.00 | -7,064.33 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.90 | 0.00 | 0.00 | 0.60 |
| Cash Conversion Cycle | -10.15 | -21.48 | -78.20 | -696.00 |